Factors affecting disease-free survival in patients with metastatic colon canser treated with EGFR infibitors

Introduction and purpose: Colorectal cansers are the most common cansers of the gastrointestinal tract. EGFR inhibitors are important in the treatment of patients diagnosed with stage 4 colorectal canser. İn our study, we aimed to investigate the factors affecting disease-free survival in patients with metastatic colon canser treated with EGFR inhibitors. Materials and methods: Patients older than 18 years of age who received treatment and follow-up in the Department of Medical Oncology at Turgut Özal Medical Center between January 2002 and December 2021 were included in the study. Retrospective data were evaluated. Patient data were obtained from patient files and ENLİL computer automation system. Results: Of the 101 patients included in the study, 69 were male and 32 were female. While the number of patients over 55 years of age was 74, the number of patients under 55 was 27. Left ivolvement was ovserved in 81 of 101 patients and right involvement was seen in 20 patients. Of 101 patients, 55 were diagnosed with rectal cancer and 46 with colon cancer. Of the patients, 59 received cetuximab and 42 received panitumumab. While metastases were identified in the liver in 47 of 101 patients; 54 of the patients had metastases outside the liver. Fifty of 101 patients received first-line treatment, while 51 patients received other-line treatments. There was no statistically significant relationship between age, gender, drug difference, primary tumor localization (diagnosis), site of involvement and disease-free survival (p>0.05); there was a significant correlation between disease-free survival and patients with liver metastases who received other step therapy (p<0.005). Conclusion: İn patients with metastatic colon cancer treated with EGFR inhibitors, a significant correlation was found between patients with liver metastases and those who received non-first-line treatment and disease-free survival. Key words: Metastatic colon canser, EGFR inhibitors, disease-free survival, age, gender, drug, diagnosis, involvement, liver, step therapy.